Students learn core subjects through adaptive software, with non-credentialed “guides” overseeing progress and activities.

Abstract: Computerized Adaptive Testing (CAT) offers an efficient and personalized method for assessing examinee proficiency by dynamically adjusting test questions based on individual performance.

Elementary and high school students across New Jersey will be taking their state assessment tests a new way this spring. The state Department of Education is changing to so-called adaptive testing, in ...

With a major change to the state's annual standardized assessment tests starting next week, some New Jersey school district leaders are frustrated by how slowly information on the change was released ...

Abstract: Computerized Adaptive Testing (CAT) is a fundamental issue in intelligent education, which aims to select a relatively small number of questions to assess student’s ability. However, ...

Chad Robins, Co-Founder, CEO & Chairman, highlighted "2025 was a remarkable year for Adaptive, marked by strong execution and meaningful progress across the business." Robins reported full-year MRD ...

Google is testing a new image AI model called "Nano Banana 2 Flash," and it's going to be faster than the Nano Banana Pro. This model is part of Gemini's Flash lineup, which is the company's fastest ...

Adaptive Biotechnologies Corporation maintains a Hold rating as MRD segment momentum is offset by competitive and valuation concerns. ADPT's Q3 top-line strength was driven by a one-time Genentech ...

Adaptive test is starting to gain traction for high-performance computing and AI chips as test programs that rely on static limits and fixed test sequences reach their practical limits. The growing ...

Abstracts featuring clonoSEQ MRD data span multiple myeloma (MM), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma ...

Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug development SEATTLE, Nov. 24, 2025 (GLOBE ...